[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sleep-apnea-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sleep-apnea-syndrome":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100648427","the-effect-of-autonomic-neuropathy-status-on-the-endpoint-events-in-diabetes-patients-with-coronary-heart-disease-and-sleep-apnea-100648427",false,"NCT07723222","The Effect of Autonomic Neuropathy Status on the Endpoint Events in Diabetes Patients With Coronary Heart Disease and Sleep Apnea.","The Effect of Autonomic Neuropathy Status on the Endpoint Events in Diabetes Patients With Coronary Heart Disease and Sleep Apnea: a Prospective Observational Cohort Study.","Inclusion Criteria:\n\n* The patient was diagnosed with coronary heart disease (coronary angiogram showed coronary artery stenosis ≥ 50%), diabetes (fasting blood glucose ≥ 7 mmol\u002FL, blood glucose ≥ 11.1 mmol\u002FL 2 hours after OGTT meal, HbA1c ≥ 6.5%, or random blood glucose ≥ 11.1 mmol\u002FL), and sleep apnea syndrome (≥ 5 apnea or hypoventilation events per hour during sleep, that is, AHI ≥ 5 times\u002Fhour, with associated symptoms or health risks. ）.\n\nExclusion Criteria:\n\n* Patients who have been implanted with permanent pacemakers; Patients with severe arrhythmia or myocardial infarction\u002Fstroke in the past 3 months; 48 hours prior to the experiment, the use of beta blockers, beta agonists ACE-I、ARB、 Patients with drugs such as adrenaline and dopamine; Pregnant women; Patients with serious diseases of important organs (such as heart, brain, kidney, liver, etc.); Patients with mental or physical disabilities; Unable to cooperate with patients undergoing examinations; Suspected or diagnosed patients with a history of alcohol or drug abuse; Patients with acute complications of diabetes, such as DKA, hypertonic coma, lactic acidosis, etc; Patients with thyroid dysfunction; Patients at risk of cardiac autonomic neuropathy (CAN), such as those with severe hypertension or proliferative retinopathy; Patients with electrolyte disorders such as hypokalemia.","ALL",{"count":18,"type":19},326,"ESTIMATED","3 Years","OBSERVATIONAL","Background: diabetes combined with cardiac autonomic neuropathy (CAN) can denervate the heart, which may prevent patients with sleep apnea syndrome from bradycardia in the early stage, and directly show an increased risk of tachyarrhythmia and sudden cardiac death. This means that many diabetes patients with sleep apnea syndrome who are at risk of sudden death may be ignored due to the lack of the typical signal of \"bradycardia\". A study showed 299 events among 165 participants, of which 132 participants (10%) had CAN and experienced 244 cardiovascular events, and 33 participants (25%) had CAN and experienced 55 cardiovascular events (hazard ratio \\[HR\\] 2.79, 95% CI 1.91). In this trial, the effect of autonomic neuropathy on the end point events of type 2 diabetes patients with coronary heart disease and sleep apnea was investigated.\n\nObjective: This study is a prospective, single-center, observational study to investigate the effect of autonomic neuropathy status on the endpoint events in patients with coronary heart disease, diabetes, and sleep apnea syndrome.\n\nMethods : Diagnosed coronary heart disease (coronary angiography showed coronary artery stenosis ≥ 50%), diabetes (fasting blood glucose ≥ 7 mmol\u002FL, blood glucose ≥ 11.1 mmol\u002FL 2 hours after OGTT meal, HbA1c ≥ 6.5%, or random blood glucose ≥ 11.1 mmol\u002FL), sleep apnea syndrome (≥ 5 apnea or hypoventilation events per hour during sleep (AHI ≥ 5 times\u002Fhour), and associated symptoms or health risks. ）The patient. The Ewing test was divided into two groups: the group without concomitant cardiac autonomic neuropathy and the group with cardiac autonomic neuropathy. The primary endpoint includes all-cause mortality events during follow-up, and the secondary endpoint includes the occurrence of cardiovascular events.\n\nThis study will explore the influence of autonomic neuropathy on the endpoint events of patients with diabetes, coronary heart disease and sleep apnea.\n\nKeywords: coronary heart disease, diabetes, sleep apnea syndrome, cardiovascular autonomic neuropathy, results",[24,25,26,27],"Coronary Heart Disease","Diabetes","Sleep Apnea Syndrome","Cardiovascular Autonomic Neuropathy (CAN)","NOT_YET_RECRUITING","2026-07-22",{"date":31,"type":32},"2026-07-23","ACTUAL",{"date":34,"type":19},"2026-08-01",{"date":36,"type":19},"2031-08-01",{"name":38,"class":39},"Xiangtan Central Hospital","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":62,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":85},"100376320","impact-of-positive-airway-pressure-therapy-on-clinical-outcomes-in-older-veterans-with-chronic-obstructive-pulmonary-disease-and-comorbid-obstructive-sleep-apnea-overlap-syndrome-100376320","NCT04179981","Impact of Positive Airway Pressure Therapy on Clinical Outcomes in Older Veterans With Chronic Obstructive Pulmonary Disease and Comorbid Obstructive Sleep Apnea (Overlap Syndrome)","Inclusion Criteria:\n\n* OSA with moderate-to-severe disease, AHI 20 per hour by in-lab polysomnography with concomitant moderate-severe COPD based on pulmonary function tests (PFTS) and with past significant history (\\>10 pack-years) of smoking\n* Male or female gender\n* Age greater than or equal to 60 years\n* Stable treatment regimen for COPD\n\nExclusion Criteria:\n\n* Current or prior treatment with PAP or oral appliance\n* Central sleep apnea defined as central apnea index \\>5 per hour and comprising 50% of AHI\n* Known primary neuromuscular diseases\n* Disorders that may impact cognitive function including:\n\n  * neurodegenerative disorders\n  * traumatic brain injury\n* untreated PTSD and\u002For history of learning disability\n* Medicines that may cause or alter sleepiness: sedative hypnotics, or stimulants as these may alter the results\n* Patient is actively suicidal due to depression, unstable mental health condition\n* Epworth sleepiness score \\>16 (severe sleepiness) or a near-miss or prior automobile accident due to sleepiness within the past 12 months\n* Narcolepsy is the primary sleep disorder, with requirement of stimulant medications\n* Employed as a commercial driver or operating heavy machinery\n* On long-term oxygen therapy prior to start of study, more than 12 hr\u002Fday\n* Patients is unable to use either a nasal or face mask (e.g., facial trauma, claustrophobia)\n* Consumption of \\>3 alcoholic beverages per day or current use of some illicit drugs, as these may contribute to cognitive deficits\n* Patients who cannot give informed consent\n* Patients receiving hospice care\n* Pregnant women due to unknown risks","60 Years",{"count":48,"type":19},668,"INTERVENTIONAL",[51],"NA","Obstructive sleep apnea (OSA) and Chronic Obstructive Pulmonary Disease (COPD) are highly prevalent chronic respiratory diseases in the Veteran population. OSA co-occurring with COPD, known as Overlap Syndrome (OVS), is a complex chronic medical condition associated with grave consequences. OVS is highly prevalent in Veterans. Veterans with OVS may be at increased risk for cognitive deficits, poor sleep quality as well as a reduced quality of life (QoL). The overall objective is to study the effects of positive airway pressure therapy on clinical outcomes in patients with OVS.",[26,54,55,56,57,58,59,60,61],"Obstructive Sleep Apnea","COPD","Overlap Syndrome","Quality of Life","Neurocognitive Function","Sleepiness","Elderly","Positive Airway Pressure",[63,64,65,66,67,68,69,70,71,72,73],"Apnea","Sleep Apnea Syndromes","Sleep Apnea, Obstructive","Nervous System Diseases","Respiration Disorders","Respiratory Tract Diseases","Signs and Symptoms, Respiratory","positive airway pressure","cognitive function","quality of life","sleepiness","RECRUITING","2026-06-03",{"date":77,"type":32},"2026-06-05",{"date":79,"type":32},"2020-12-01",{"date":81,"type":19},"2027-12-31",{"name":83,"class":84},"VA Office of Research and Development","FED",1]